DOCSLIB.ORG

Volume 85, Supplement 1, October 2019 ISSN 0145-2126 Clive S. Zent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Volume 85, Supplement 1, October 2019 ISSN 0145-2126 Clive S. Zent Volume 85, Supplement 1, October 2019 ISSN 0145-2126 Supplement Abstracts of the Xth Eurasian Hematology Oncology Congress 8–11 October 2019 Istanbul, Turkey Editor-in-Chief Clive S. Zent USA Associate Editors Karl-Anton Kreuzer Germany David Ross Australia Publication of this abstract book is sponsored by the Eurasian Hematology Oncology Congress Supplement Abstracts of the Xth Eurasian Hematology Oncology Congress 8–11 October 2019, Istanbul, Turkey EHOC 2019 Publication of this abstract book is sponsored by the Eurasian Hematology Oncology Congress Symposium abstracts are published as submitted or with minor editing only. Leukemia Research is not responsible for errors or omissions in the abstracts. AMSTERDAM x BOSTON x LONDON x NEW YORK x OXFORD x PARIS x PHILADELPHIA x SAN DIEGO x ST. LOUIS Published monthly Storage or Usage Publication information: Leukemia Research (ISSN 0145-2126). For 2019, Except as outlined above or as set out in the relevant user license, no part of volumes 77–88 (12 issues) are scheduled for publication. Subscription prices are this publication may be reproduced, stored in a retrieval system or transmitted available upon request from the Publisher or from the Elsevier Customer Service in any form or by any means, electronic, mechanical, photocopying, recording Department nearest you or from this journal’s website (http://intl.elsevierhealth. or otherwise, without prior written permission of the publisher. com/journals/lere). Further information is available on this journal and other Elsevier products through Elsevier’s website: (http://www.elsevier.com). Permissions Subscriptions are accepted on a prepaid basis only and are entered on a calendar For information on how to seek permission visit www.elsevier.com/ year basis. Issues are sent by standard mail (surface within Europe, air delivery permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA). outside Europe). Priority rates are available upon request. Claims for missing Author rights issues should be made within six months of the date of dispatch. Author(s) may have additional rights in their articles as set out in their agreement Advertising information. Advertising orders and inquiries can be sent to: with the publisher (more information at http://www.elsevier.com/authorsrights). Nicholas Dunwell, Account Executive, Elsevier Ltd. 32 Jamestown Road, Language (Usage and Editing services) London, NW1 7BY, UK Tel.: +44 (0) 20 7424 4383 Fax: +44 (0) 20 7424 4433 Please write your text in good English (American or British usage is accepted, Email: [email protected]. For inquiries relating to Commercial Sales but not a mixture of these). Authors who feel their English language and Supplements please contact: Eva Nagtegaal, Account Manager, Conference manuscript may require editing to eliminate possible grammatical or spelling Information Publishing Elsevier B.V. Radarweg 29 Amsterdam 1043 NX errors and to conform to correct scientific English may wish to use the English Netherlands Tel.: +31 20 485 3984 Fax: 0031 20 485 2940 Email: e.nagtegaal@ Language Editing service available from Elsevier’s WebShop http://webshop. elsevier.com elsevier.com/languageediting/ or visit our customer support site http:// USA mailing notice: Leukemia Research (ISSN 0145-2126) is published service.elsevier.com for more information. monthly by Elsevier Ltd (The Boulevard, Langford Lane, Kidlington, Oxford Illustration services OX5 1GB, UK). Periodicals postage paid at Jamaica, NY 11431 and additional Elsevier’s WebShop (http://webshop.elsevier.com/illustrationservices) offers mailing offices. Illustration Services to authors preparing to submit a manuscript but concerned USA POSTMASTER: Send change of address to Leukemia Research, Elsevier about the quality of the images accompanying their article. Elsevier’s expert Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO illustrators can produce scientific, technical and medical-style images, as well 63043, USA. as a full range of charts, tables and graphs. Image ‘polishing’ is also available, AIRFREIGHT AND MAILING in USA by Air Business Ltd., c/o Worldnet Shipping where our illustrators take your image(s) and improve them to a professional Inc, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. standard. Please visit the website to find out more. Aims and Scope Notice leukemia Research is an international journal which brings comprehensive Practitioners and researchers must always rely on their own experience and and current information to all health care professionals involved in basic and knowledge in evaluating and using any information, methods, compounds (or) applied clinical research in leukemias, lymphomas, multiple myeloma or experiments described herein. Because of rapid advances in the medical and other hematologic malignancies. The editors encourage the submission sciences, in particular, independent verification of diagnoses and drug dosages of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell should be made. To the fullest extent of the law, no responsibility is assumed by biology, immunology and molecular biology as well as epidemiologic and the publisher for any injury and/or damage to persons or property as a matter clinical studies. of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Specifically, of major interest will be articles that encompass the application of oncogenes, growth factors, cell markers, cell cycle and differentiation Although all advertising material is expected to conform to ethical (medical) agents, novel therapeutics and clinical trials in both the acute and chronic standards, inclusion in this publication does not constitute a guarantee or leukemias as well as the myelodysplastic syndromes. In addition, we solicit endorsement of the quality or value of such product or of the claims made of selected articles on the rapidly increasing specialty of marrow or stem cell it by its manufacturer. reconstitution after high dose therapy with curative attempt in patients with Author inquiries a wide range of neoplasms. You can track your submitted article at http://www.elsevier.com/track- © 2019 Elsevier Ltd. submission. You can track your accepted article at http://www.elsevier.com/ trackarticle. You are also welcome to contact Customer Support via http:// This journal and the individual contributions contained in it are protected service.elsevier.com under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has Guide for Authors been applied by the publisher to an individual article: For a full and complete Guide for Authors, please go to http://www.elsevier. com/locate/leukres or http://ees.elsevier.com/lr/ Photocopying Single photocopies of single articles may be made for personal use Orders, claims, and journal inquiries: please contact the Elsevier Customer as allowed by national copyright laws. Permission is not required for Service Department nearest you: photocopying of articles published under the CC BY license nor for St. Louis: Elsevier Customer Service Department, 3251 Riverport Lane, photocopying for non-commercial purposes in accordance with any other Maryland Heights, MO 63043, USA; phone: (877) 6542452 [toll free within the user license applied by the publisher. Permission of the publisher and USA]; (+1) (314) 4478871 [outside the USA]; fax: (+1) (314) 4478029; e-mail: payment of a fee is required for all other photocopying, including multiple [email protected] or systematic copying, copying for advertising or promotional purposes, Oxford: Elsevier Customer Service Department, The Boulevard, Langford Lane, resale, and all forms of document delivery. Special rates are available for Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) educational institutions that wish to make photocopies for non-profit (1865) 843970; e-mail: [email protected] educational classroom use. Tokyo: Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, Derivative Works 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) Users may reproduce tables of contents or prepare lists of articles including 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@ abstracts for internal circulation within their institutions or companies. Other elsevier.com than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or Singapore: Elsevier Customer Service Department, 3 Killiney Road, #08-01 company. Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: [email protected] For any subscribed articles or articles published under a CC BY-NC-ND license, ϱ permission of the publisher is required for all other derivative works, including The paper used in this publication meets the requirements of ANSI/NISO compilations and translations. Z39.48-1992 (Permanence of Paper) EDITOR-IN-CHIEF Clive S. Zent, University of Rochester Medical Center, Rochester, NY, USA ASSOCIATE EDITORS Karl-Anton Kreuzer, Universität zu Köln, Cologne, Germany David Ross, Flinders Medical Centre, South Australia, Australia EDITORIAL OFFICE email: [email protected] EDITORIAL BOARD I. Abraham, USA Q. Jiang, China A.
Load more

Recommended publications
  • Time Course of Immune Recovery and Viral Reactivation Following Hematopoietic Stem Cell Transplantation
    CLINICAL ARTICLES Cellular Therapy and Transplantation (CTT). Vol.5, No.4 (17), 2016 doi: 10.18620/ctt-1866-8836-2016-5-4-32-43 Submitted:02 November 2016, accepted: 09 December 2016 Time course of immune recovery and viral reactivation following hematopoietic stem cell transplantation 1Olga S. Pankratova, 2Alexei B. Chukhlovin 1Tampere University Hospital, Tampere, Finland 2R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, The St. Petersburg State I. Pavlov Medical University CD8+ cells specific for cytomegalovirus (CMV), or Ep- Summary stein-Barr virus (EBV) rapidly expand in cases of CMV or EBV activation. Total depletion of innate and adaptive immune cell pop- ulations occurs after intensive chemotherapy and he- Despite recovery of absolute B-cell counts by day 30 matopoietic stem cell transplantation (HSCT) then fol- post-HSCT, their functions, i.e., antigen-specific anti- lowed by gradual recovery of immune populations, due body production, are reduced for months and years after to progenitors derived from donor hematopoietic cells HSCT, due to slow restoration of mature immune cell which differentiate to myeloid and lymphoid lineages. populations, thus resemling normal evolution of B cell Time dynamics of immune reconstitution and differen- hierarchy in human organism. tial maturation of distinct immune populations is only partially evaluated, especially, at early terms post-trans- Reactivation of herpesviruses (mostly, CMV, EBV and plant. E.g., innate immunity is restored within 1st month Herpes Simplex) is a known feature of immune de- after HSCT, due to rapid reconstitution of granulocytes, ficiency. Timing of maximal herpesvirus incidence monocytes, and natural killer (NK) cells.
    [Show full text]
  • Chapter 118: Transplantation-Related Malignancies
    CHAPTER 118 — REFERENCES 1. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following 30. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro in- bone marrow transplantation. Blood 1996;87:3633–3639. teract to alter therapy-related acute myeloid leukemia susceptibility. Blood 2. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone 2008;112:741–749. marrow transplantation for leukemia or aplastic anemia. N Engl J Med 31. Casorelli I, Offman J, Mele L, et al. Drug treatment in the development 1989;321:784–789. of mismatch repair defective acute leukemia and myelodysplastic syndrome. 3. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow DNA Repair (Amst) 2003;2:547–559. transplantation. N Engl J Med 1997;336:897–904. 32. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 4. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leuke- promoter and its association with microsatellite instability in acute myeloid mia and myelodysplasia following autologous transplantation for lymphoma: leukemia. Leukemia 2003;17:83–88. an assessment of risk factors. Blood 2000;95:1588–1593. 33. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved 5. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodg- in homologous recombination repair interact to increase the risk of develop- kin’s disease after allogeneic bone marrow transplantation. J Clin Oncol ing acute myeloid leukemia. Clin Cancer Res 2004;10:2675–2680. 1999;17:3122–3127. 34. Matullo G, Palli D, Peluso M, et al.
    [Show full text]
  • Autotransplantation of the Third Molar: a Therapeutic Alternative to the Rehabilitation of a Missing Tooth: a Scoping Review
    bioengineering Review Autotransplantation of the Third Molar: A Therapeutic Alternative to the Rehabilitation of a Missing Tooth: A Scoping Review Mario Dioguardi 1,* , Cristian Quarta 1 , Diego Sovereto 1, Giuseppe Troiano 1 , Michele Melillo 1, Michele Di Cosola 1, Angela Pia Cazzolla 1 , Luigi Laino 2 and Lorenzo Lo Muzio 1 1 Department of Clinical and Experimental Medicine, University of Foggia, Via Rovelli 50, 71122 Foggia, Italy; [email protected] (C.Q.); [email protected] (D.S.); [email protected] (G.T.); [email protected] (M.M.); [email protected] (M.D.C.); [email protected] (A.P.C.); [email protected] (L.L.M.) 2 Multidisciplinary Department of Medical-Surgical and Odontostomatological Specialties, University of Campania “Luigi Vanvitelli”, 80121 Naples, Italy; [email protected] * Correspondence: [email protected] Abstract: Introduction: Tooth autotransplantation is the repositioning of an erupted, partially erupted, or non-erupted autologous tooth from one site to another within the same individual. Several factors influence the success rate of the autotransplant, such as the stage of root development, the morphology of the tooth, the surgical procedure selected, the extraoral time, the shape of the recipient socket, the vascularity of the recipient bed, and the vitality of the cells of the periodontal ligament. The aim of this scoping review was to provide the most up-to-date information and data on the clinical principles of the third-molar autograft and thus provide clinical considerations for its success. Citation: Dioguardi, M.; Quarta, C.; Materials and methods: This review was conducted based on PRISMA-ScR (Preferred Reporting Sovereto, D.; Troiano, G.; Melillo, M.; Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews).
    [Show full text]
  • A Nationwide Analysis of Kidney Autotransplantation
    A Nationwide Analysis of Kidney Autotransplantation ZHOBIN MOGHADAMYEGHANEH, M.D., MARK H. HANNA, M.D., REZA FAZLALIZADEH, M.D., YOSHITSUGU OBI, M.D., PH.D., CLARENCE E. FOSTER, M.D., MICHAEL J. STAMOS, M.D., HIROHITO ICHII, M.D., PH.D. From the Department of Surgery, University of California, Irvine, School of Medicine, Orange, California There are limited data regarding outcomes of patients underwent kidney autotransplantation. This study aims to investigate outcomes of such patients. The nationwide inpatient sample database was used to identify patients underwent kidney autotransplantation during 2002 to 2012. Multivariate analyses using logistic regression were performed to investigate morbidity predictors. A total of 817 patients underwent kidney autotransplantation from 2002 to 2012. The most common indication of surgery was renal artery pathology (22.7%) followed by ureter pathology (17%). Overall, 97.7 per cent of operations were performed in urban teaching hospitals. The number of procedures from 2008 to 2012 were significantly higher compared with the number of them from 2002 to 2007 (473 vs 345, P < 0.01). The overall mortality and morbidity of patients were 1.3 and 46.2 per cent, respectively. The most common postoperative complications were transplanted kidney failure (10.7%) followed by hemorrhagic complications (9.7%). Obesity [adjusted odds ratio (AOR): 9.62, P < 0.01], fluid and electrolyte disorders (AOR: 3.67, P < 0.01), and preoperative chronic kidney disease (AOR: 1.80, P 5 0.03) were predictors of morbidity in patients. In conclusion, Kidney autotransplantation is associated with low mortality but a high morbidity rate. The most common indications of kidney autotransplantation are renal artery and ureter pathologies, respectively.
    [Show full text]
  • Outpatient Immunosuppressive Drugs Under Medicare
    Outpatient Immunosuppressive Drugs Under Medicare July 1991 OTA-H-452 NTIS order #PB92-117720 Recommended Citation: U.S. Congress, Office of Technology Assessment, Outpatient Immunosuppressive Drugs Under Medicare, OTA-H-452 (Washington, DC: U.S. Government Printing Office, Septem- ber 1991). For sale by the U.S. Government Printing Office Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328” ISBN 0-16 -035315-7 Foreword Of all the astonishing achievements of modern medicine, the ability to successfully transplant a living organ from one human being to another is perhaps one of the most awesome. Immunosuppressive drugs are one of the spectrum of technological advances that have made organ transplants an everyday phenomenon. At the same time, however, transplant recipients’ needs for these drugs have presented Medicare with a continuing policy dilemma, because Medicare does not usually pay for outpatient prescription drugs. In 1984, the year after cyclosporine made its debut onto the health care market, OTA reported to Congress on the likely benefits of the drug for Medicare kidney transplant recipients. The present report, requested by the Senate Committee on Finance in the wake of the repeal of the Medicare Catastrophic Coverage Act, examines Medicare’s current immunosuppressive drug coverage dilemma and the policy tradeoffs it entails for the 1990s. OTA reports would not be possible without the assistance and input of a wide variety of individuals from both the public and the private sectors. OTA staff and contractors gratefully acknowledge the contributions of the many people who provided data, clarified facts, presented views, and reviewed the drafts of this report.
    [Show full text]
  • Xenotransplantation of Ovarian Tissue Into Male
    XENOTRANSPLANTATION OF OVARIAN TISSUE INTO MALE IMMUNODEFICIENT MICE by HUGO JOSE HERNANDEZ FONSECA (Under the direction of BENJAMÍN G. BRACKETT) ABSTRACT A male immunodeficient mouse model for transplantation of ovarian tissue was investigated. Bovine and human ovarian tissues were surgically placed either under the kidney capsule or in the subcutaneous spaces of male non obese diabetic (NOD) severe combined immunodeficient (SCID) mice. Time intervals required for development of growing follicles were determined for neonatal and adult bovine ovarian tissue grafts. This interval was much shorter (P <0.01) in adult tissue than in one-week-old calf tissue, i.e. 55 vs 124 days. The increase in the proportion of growing follicles was coincidental with a decrease in the proportion of resting follicles. This increment in the growing follicle populations took place abruptly and was significant by 55 days and by 124 days after transplantation in the adult cow and calf ovarian grafts, respectively. Recovery of oocytes from bovine ovarian grafts was successful. Several immature oocytes were recovered and evidence of maturation in one oocyte was obtained after 24 hours of in vitro maturation. Treatment of host mice with an FSH:LH preparation increased follicular development but did not enhance oocyte recovery rates. Human ovarian tissue grafted under the kidney capsule of intact male NOD SCID mice showed a greater proportion of growing follicles than similar grafts transplanted to the kidney of castrated hosts and to the subcutaneous space of intact hosts. However, no differences in follicular growth and development were detected between the intact/ kidney capsule and the castrated / subcutaneous groups.
    [Show full text]
  • Ex Vivo Resection and Autotransplantation for Pancreatic Neoplasms
    Ex Vivo Resection and Autotransplantation for Pancreatic Neoplasms Peter Liou, MD, Tomoaki Kato, MD, MBA* KEYWORDS Pancreas Pancreatic tumors Ex vivo resection Autotransplantation Mesenteric root involvement SMA involvement KEY POINTS Ex vivo resection and autotransplantation is a technique derived from multivisceral and intestinal transplantation whereby tumor-infiltrated organs are removed en bloc and pre- served in the cold, followed by tumor resection and reimplantation of the remaining viscera. Advantages of ex vivo resection include tumor removal in a bloodless field while mini- mizing the risk of ischemic injury to the involved organs. Access to the mesenteric root is greatly facilitated with ex vivo resection, and allows for safe reconstruction of major vasculature while preserving visceral integrity. Certain low-grade, non-adenocarcinomatous pancreatic neoplasms involving the mesen- teric vessels where aggressive surgical resection would be warranted, may benefit from ex vivo resection. Although ex vivo resections have been performed for pancreatic adenocarcinomas with major arterial involvement, the associated morbidity is significant and benefit remains unclear. INTRODUCTION Pancreatic neoplasms are a heterogeneous group of tumors arising from the pancreas with distinct and varied clinical profiles.1 Although pancreatic adenocarcinoma remains by far the most common and deadliest of these, there are several low- grade or benign neoplasms that may benefit from aggressive, curative resection.2,3 Due to the proximity of the pancreas to major abdominal vasculature, these tumors can sometimes infiltrate these vessels and preclude complete or safe resection by conventional surgical technique. Ex vivo resection and autotransplantation, whereby Financial Disclosures: The authors have nothing to disclose. Department of Surgery, Columbia University Medical Center, 622 West 168 Street PH14-105, New York, NY 10032, USA * Corresponding author.
    [Show full text]
  • (CTA) of the Face
    National Consultative Ethics Committee for Health and Life Sciences Opinion N°82 Composite tissue allotransplantation (CTA) of the face (Full or partial facial transplant) Membership of the Working Group: Monique Canto-Sperber (moderator) Chantal Deschamps Marie-Jeanne Dien Jean Michaud Denys Pellerin (moderator) Experts consulted: Docteur Laurent Lantieri Docteur Jean-Dominique Favre Monsieur André Matzneff Médecin général Alain Bellavoir On February 19 th 2002, Doctor Lantieri of the Henri Mondor (AH-HP) Hospital, referred to CCNE concerning the ethical issue of vascularised composite tissue allotransplantation of the face. In support of his request, he submitted a report called — Cutaneous allotransplantations œ ethical and medical issues “ so as to — initiate a discussion on problems which may arise following reconstruction of the body image “. 1 The present Opinion is only concerned with the possibility of full or partial facial reconstruction by composite tissue allotransplantation, for people who have suffered disfigurement following accidents, burns, explosions, or disease. It does not deal with plastic surgery which aims to improve physical appearance in the absence of initial trauma or disease. Outline of the Report I. Current status. Surgical data 1. Autotransplantation and allotransplantation 2. Problems arising out of rejection and lifelong immunosuppression treatment 3. Is CTA facial reconstruction possible? II. Current indications for facial reconstruction 1. Ballistic trauma 2. Facial cancers 3. Extensive facial burns 4. Some congenital malformations of the face III. Ethical issues regarding the human face 1. The ethical significance of the human countenance 2. The sorrow of no longer having a face IV. Ethical issues regarding the use of CTA 1.
    [Show full text]
  • June 4–9, 2021
    THE SCIENCE OF TOMORROW STARTS TODAY ATC2021 VirtualCONNECT atcmeeting.org JUNE 4–9, 2021 Registration Brochure & Scientific Program DISCOUNTED REGISTRATION DEADLINE MAY 5, 2021 #ATC2021VirtualConnect ATC2021 VirtualCONNECT All-New Enhanced Experience! We are excited to announce ATC 2021 Virtual Live Connect, an all-new, completely enhanced virtual Broadcast Dates: meeting experience. Gain immediate access to innovators in the field and have your voice heard June 4 – 9, 2021 through various types of interaction Real-Time Interactivity Over 200 Education Credit The 2021 program will provide ample and Contact Hours opportunities for real-time interactivity through: ATC provides CME, ANCC, ACPE, and ABTC credits/contact hours. Yearlong access allows • Live Video Discussions you to take advantage of the over 200 • Invigorating Q&A Discussions Post- credits/contact hours available. This is the Presentation most credits/contact hours ATC has ever been • Live Presentations by Abstract Presenters able to provide! • Engaging, Unconventional Networking Breaks Continue to check the ATC website for final • Live Symposia Presentations credit/contact hour details, www.atcmeeting.org. Mobile Responsive Access In-Depth Symposia Included You’ll be able to access Virtual Connect on-the-go, in Virtual Connect earn your education credit or contact hours, hear Included with ATC 2021 Virtual Connect are the latest innovations, and build your professional 9 In-Depth Symposia. These symposia will be network – all from the comfort and safety of your live broadcasted on Friday, June 4, 2021, and home or office. then available in the OnDemand format until June 3, 2022. Yearlong Access to OnDemand Content Time Zone Schedule of By registering to attend ATC 2021 Virtual Connect, Program – Eastern Time Zone you also will gain yearlong access to all Live The program schedule is built in Eastern Time Broadcast sessions available in an OnDemand Zone.
    [Show full text]
  • Overnight Storage of Autologous Stem Cell Apheresis Products Before
    Bone Marrow Transplantation (2006) 38, 609–614 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation MD Parkins1, N Bahlis1,2, C Brown1,2, L Savoie1,2, A Chaudhry2, JA Russell1,2 and DA Stewart1,2 1Department of Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada and 2Department of Oncology, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada To reduce costs and avoid inconvenient overtime work, our Introduction institution changed policy in September 2000 so that autologous stem cell apheresis products were stored Numerous reports have demonstrated that the single most overnight before cryopreservation rather than immedi- important predictor of engraftment following autologous ately processed. This retrospective reviewwasconducted stem cell transplantation (ASCT) is the CD34 þ dose, to evaluate the possible impact of this policy change on with minimum and preferred targets of 2.0 Â 106 and hematopoietic engraftment following autologous stem cell 5.0 Â 106 cells/kg, respectively.1,2 In order to achieve these transplantation (ASCT). In total, 229 consecutive lym- targets, multiple apheresis procedures may be required. phoma patients who underwent a single, unpurged ASCT Cryopreservation of the autograft is usually carried out in Calgary between January 1995 and November 2003 within 2–4 h following the collection. Current cryopreser- were evaluated. Of these patients, 131 patients’ autografts vation practices are technically demanding and may require underwent immediate processing and cryopreservation experienced laboratory personnel to work extended hours before September 2000, and 98 patients’ autografts in order to process samples on the day of collection.
    [Show full text]
  • Platelet Transfusion Requirements During Autologous Peripheral Blood Progenitor Cell Transplantation Correlate with the Pretransplant Platelet Count
    Bone Marrow Transplantation, (1997) 20, 459–463 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count BJ Bolwell, M Goormastic, S Andresen, B Overmoyer, B Pohlman and M Kalaycio Department of Hematology and Medical Oncology, at the Cleveland Clinic Foundation, Cleveland, OH, USA Summary: after the infusion of autologous marrow.1,2 The use of primed peripheral blood progenitor cells (PBPC) has The use of primed peripheral blood progenitor cells resulted in more rapid platelet engraftment, with most trials (PBPC) has improved platelet engraftment following reporting platelet recovery in 14–18 days.3–8 Relatively few autologous bone marrow/PBPC transplantation series specifically report the number of platelet transfusions (ABMT). The thrombocytopenia associated with ABMT required during autologous transplantation when using generally lasts 14–18 days, and is associated with vari- PBPC. At our own institution, a median of five platelet able platelet transfusion requirements. Little, if any, transfusions are required during PBPC autologous trans- data exist examining prognostic parameters for platelet plantation. transfusion requirements during autologous transplan- Many studies have documented that both neutrophil and tation. We retrospectively examined 286 consecutive platelet engraftment correlates with the number of CD34+ patients undergoing autologous transplantation from 1 cells infused.9–12 However, little data exist examining other January l994 to 1 June l996 with respect to platelet potential prognostic parameters for platelet engraftment, or engraftment and platelet transfusion requirements. One for the number of platelet transfusion events required dur- hundred and fifty four patients were transplanted for ing autologous transplantation.
    [Show full text]
  • First Successful Delivery After Uterus Transplantation in MHC-Defined
    Journal of Clinical Medicine Article First Successful Delivery after Uterus Transplantation in MHC-Defined Cynomolgus Macaques Iori Kisu 1,* , Yojiro Kato 2, Yohei Masugi 3, Hirohito Ishigaki 4 , Yohei Yamada 5 , Kentaro Matsubara 6, Hideaki Obara 6, Katsura Emoto 3, Yusuke Matoba 1, Masataka Adachi 1, Kouji Banno 1, Yoko Saiki 7, Takako Sasamura 4, Iori Itagaki 8, Ikuo Kawamoto 8, Chizuru Iwatani 8, Takahiro Nakagawa 8, Mitsuru Murase 8, Hideaki Tsuchiya 8, Hiroyuki Urano 9, Masatsugu Ema 8, Kazumasa Ogasawara 4, Daisuke Aoki 1, Kenshi Nakagawa 9 and Takashi Shiina 10 1 Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 1608582, Japan; [email protected] (Y.M.); [email protected] (M.A.); [email protected] (K.B.); [email protected] (D.A.) 2 Department of Surgery, Division of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo 1428555, Japan; [email protected] 3 Department of Pathology, Keio University School of Medicine, Tokyo 1608582, Japan; [email protected] (Y.M.); [email protected] (K.E.) 4 Department of Pathology, Shiga University of Medical Science, Shiga 5202192, Japan; [email protected] (H.I.); [email protected] (T.S.); [email protected] (K.O.) 5 Department of Pediatric Surgery, Keio University School of Medicine, Tokyo 1608582, Japan; [email protected] 6 Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan; [email protected] (K.M.); [email protected] (H.O.) 7 Department of Anesthesiology, Saiseikai Kanagawaken
    [Show full text]